Skip to content

Quality of Life and High-Risk Abdominal Cancer Surgery

Changes of Health-related Quality of Life 6 Months After High-risk Oncological Upper Gastrointestinal and Hepatobiliary Surgery: a Single-centre Prospective Observational Study (ChangeQol Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04444544
Acronym
ChangeQoL
Enrollment
295
Registered
2020-06-23
Start date
2020-09-05
Completion date
2025-07-20
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Frailty, Quality of Life, Surgery

Keywords

Quality of Life, Surgery, Regret

Brief summary

The investigators plan to measure the changes of health-related quality of life (HRQoL) at 6 months and 12 months after the following high-risk oncological abdominal surgery: gastrectomy, esophagectomy, pancreatectomy and hepatectomy. The investigators will measure the HRQoL using the validated EORTC QLQ-C30 questionnaire before and at 6 months and 12 month after the surgery. The investigators will identify phenotypes of HRQoL changes (improvement, stability and deterioration) at 6 months and 12 months after surgery. The second aim is to assess the regret of the patient at 6 months and 12 months regarding his/her decision to undergo surgery. The investigators will also assess the regret of the next of kin at 6 months regarding the decision to undergo surgery. This descriptive, prospective, observational, single-centre cohort study aims to: identify phenotypes of HRQoL changes after abdominal surgical oncology (improvement, stability and deterioration); assess the regret of patients regarding their decision to undergo surgical oncology at 6 months and 12 months; assess the regret of the next of kin regarding the decision of the patient to undergo surgical oncology at 6 months and 12 months. The investigators will include patients scheduled for the following elective abdominal cancer surgery: gastrectomy; esophagectomy; pancreas resection and hepatectomy. The investigators will assess HRQoL using the validated EORTC QLQ-C30 Summary Score before and 6 months and 12 months after surgery. The cut-offs for the three phenotypes of HRQoL changes will be defined using the minimal clinically important difference (MCID) of 10 points. The investigators will assess regret using the Decision Regret Scale (DRS) at 6 months and 12 months after surgery. The expected results are: The investigators can identify phenotypes of HRQoL changes after surgical oncology using the EORTC QLQ-C30 Summary Score; the investigators will describe the distribution of these phenotypes and will find an association with the pre-existing frailty. The investigators can describe the extent of the regret of the patient and of the next of kin at 6 months using the DRS. The investigators will observe an association between the DRS score at 6 months and the HRQoL Summary Score change. The investigators will not observe a relationship between the DRS score of patients and next-of-kins.

Detailed description

The full protocol has been published: DOI 10.1136/bmjopen-2022-065902

Interventions

OTHERHigh Risk Abdominal Surgery

Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Adult patients (\>18 years) scheduled for the following elective abdominal cancer surgery known for high one-year mortality4: gastrectomy; esophagectomy; pancreas resection and hepatectomy

Exclusion criteria

* Patients with inoperable tumours; i.e. some patients will be excluded at the time of surgery if unexpected advanced tumour staging is confirmed intraoperatively (e.g. peritoneal carcinomatosis or any other diagnosis without therapy). * Hepatectomy for metastasectomy * Mentally impaired patients (known diagnosis) * Psychotic diagnoses (i.e. schizophrenia) * Dementia (mini mental score (MMSE) \< 18) * Incapacity to understand the information sheet * Blindness (unable to perform the visual part of the mini-mental state examination)

Design outcomes

Primary

MeasureTime frameDescription
Health-related Quality of Life6 months after surgeryEORTC-QLQ C30. Minimum 0, Maximum 100

Secondary

MeasureTime frameDescription
Regret6 and 12 months after surgeryDecision Regret Scale. Minimum 0, Maximum 100
Health-related Quality of Life12 months after surgeryEORTC-QLQ C30. Minimum 0, Maximum 100

Countries

Switzerland

Contacts

STUDY_DIRECTORBernhard Walder, MD

University Hospitals of Geneva - Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026